Barinthus Biotherapeutics plc
BRNS
$0.74
-$0.02-2.49%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -50.67% | 298.53% | 442.03% | -178.17% | -31.80% |
| Gross Profit | 50.67% | -298.53% | -442.03% | -97.89% | 31.80% |
| SG&A Expenses | -55.06% | -81.31% | 144.50% | -62.69% | 117.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 61.54% | 86.02% | 63.10% | -- | 97.75% |
| Total Operating Expenses | -50.97% | -71.66% | 191.40% | -57.97% | 26.43% |
| Operating Income | 50.97% | 71.66% | -191.40% | -9.25% | -26.43% |
| Income Before Tax | 49.78% | 71.80% | 45.79% | -80.05% | -24.78% |
| Income Tax Expenses | 8.00% | 27.27% | -2,000.00% | -2,266.67% | -257.14% |
| Earnings from Continuing Operations | 49.83% | 71.85% | 46.08% | -79.25% | -24.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 850.00% | -70.00% | -74.51% | -66.67% | -83.33% |
| Net Income | 49.91% | 71.85% | 46.01% | -79.52% | -24.77% |
| EBIT | 50.97% | 71.66% | -191.40% | -9.25% | -26.43% |
| EBITDA | 49.21% | 71.17% | -336.68% | -16.58% | -24.31% |
| EPS Basic | 50.53% | 72.25% | 46.90% | -74.05% | -20.73% |
| Normalized Basic EPS | 51.45% | 73.08% | -410.95% | -11.82% | -22.36% |
| EPS Diluted | 50.34% | 71.43% | 46.90% | -71.43% | -20.73% |
| Normalized Diluted EPS | 51.45% | 73.08% | -410.95% | -11.82% | -22.36% |
| Average Basic Shares Outstanding | 1.25% | 1.45% | 1.69% | 3.15% | 3.34% |
| Average Diluted Shares Outstanding | 1.25% | 1.45% | 1.69% | 3.15% | 3.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |